CDXS - NASDAQ

Codexis, Inc.

CDXS·NASDAQ

$2.72

+1.1%

HealthcareBiotechnology

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$247.24M

EPS-0.5000

P/E Ratio-5.44

Earnings Date08/12/2026

147.80M

Assets

-1%

3Y-41.0%

5Y-33.0%

10Y+315.0%

97.27M

Total Liabilities

18%

3Y-8.0%

5Y+89.0%

10Y+488.0%

50.53M

Total Equity

-25%

3Y-65.0%

5Y-70.0%

10Y+165.0%

Codexis, Inc. Funding & Solvency Profile

CDXS · NASDAQ

Current Assets

Cash & Cash Equivalents50.79M

Net Receivables10.73M

Inventory1.82M

Other Current Assets6.06M

Total Current Assets97 M

Non-Current Assets

Property, Plant & Equipment43.52M

Goodwill & Intangible Assets2.46M

Long-Term Investments2.50M

Other Non-Current Assets2.50M

Total Non-Current Assets49 M

Total Assets

147.80M

Financial Health Analysis

Current Ratio

3.82x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.92x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

71 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

66% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Codexis, Inc. Balance Sheet

CDXS • NASDAQ

Codexis, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	50.8M	19.3M	65.1M	114M	116.8M	149.1M	90.5M	53M	31.2M	19.2M	23.3M	26.5M	22.1M	32M	25.8M	72.4M	31.8M	21.9M	55.1M	32.2M
Short-Term Investments	27.4M	54.2M	0.0	0.0	0.0	1M	0.0	0.0	0.0	0.0	0.0	0.0	3M	13.5M	27.7M	0.0	23.8M	15.2M	29M	0.0
Cash & Short-Term Investments	78.2M	73.5M	65.1M	114M	116.8M	150.1M	90.5M	53M	31.2M	19.2M	23.3M	26.5M	25.1M	45.5M	53.5M	72.4M	55.6M	37.1M	84.1M	32.2M
Net Receivables	10.7M	18.9M	19.9M	40.9M	37.7M	29.3M	20.2M	13.5M	11.8M	5.9M	7.3M	3.9M	5.4M	7.5M	18.9M	15.3M	7.2M	6.2M	6.4M	2.8M
Accounts Receivables	10.7M	11.8M	10M	31.7M	24.5M	29.3M	20.2M	11.6M	11.4M	5.9M	7.3M	3.9M	5.4M	7.5M	18.9M	15.3M	7.2M	6.2M	6.4M	2.8M
Other Receivables	0.0	7.1M	10M	9.1M	13.1M	0.0	0.0	2M	353K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	1.8M	1.8M	2.7M	2M	1.2M	964K	371K	589K	1M	825K	992K	1.4M	1.5M	1.3M	4.5M	2.8M	2.9M	3M	1.6M	970K
Prepaids	0.0	0.0	0.0	5.5M	5.7M	3.4M	2.5M	1.1M	984K	1.2M	1.2M	1.3M	1.6M	5.4M	2.3M	1.6M	1.7M	1.7M	1.2M	674K
Other Current Assets	6.1M	4.6M	5.7M	521K	579K	638K	661K	0.0	984K	1.2M	1.2M	0.0	2.2M	5.4M	2.3M	0.0	-68M	366K	1.6M	0.0
Total Current Assets	96.8M	98.8M	93.5M	162.9M	161.9M	184.4M	114.2M	67.2M	45M	27.2M	32.8M	33M	35.8M	59.8M	79.2M	92.2M	67.4M	48.3M	93.3M	36.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	43.5M	42.9M	28.6M	61.9M	65.5M	31.2M	30.4M	4.8M	2.8M	2.2M	3.1M	4M	8.4M	16.7M	24.2M	21.5M	21.6M	16M	11.1M	4.5M
Goodwill	2.5M	2.5M	2.5M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.1M	3.1M	1.9M
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8M	6.2M	9.6M	12.9M	16.4M	20.2M	928K	1.8M	2.8M	2.3M
Goodwill & Intangible Assets	2.5M	2.5M	2.5M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	3.2M	6.1M	9.4M	12.8M	16.2M	19.7M	23.4M	4.2M	4.9M	5.9M	4.3M
Long-Term Investments	2.5M	2.8M	9.7M	20.5M	14M	1.5M	1.1M	588K	671K	1.1M	1.5M	688K	795K	3.6M	10.3M	0.0	0.0	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	-1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	2.5M	2.1M	2.3M	1.9M	1.8M	1.4M	1.2M	2.5M	1.9M	1.9M	1.1M	1M	1M	3.7M	2.5M	4.3M	5.9M	1.6M	3.2M	1.3M
Total Non-Current Assets	51M	50.2M	43.1M	87.5M	84.5M	37.2M	34.9M	11.1M	8.6M	8.4M	11.8M	15.1M	23.1M	40.2M	56.7M	49.1M	31.7M	22.5M	20.2M	10M
Total Assets	147.8M	149M	136.6M	250.4M	246.4M	221.6M	149.1M	78.3M	53.6M	35.6M	44.6M	48.1M	58.8M	100M	135.9M	141.3M	99M	70.9M	113.5M	46.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.6M	2.8M	5.9M	3.2M	3M	3M	2.6M	3.1M	3.5M	4.2M	3.4M	4.7M	4M	3.7M	10.4M	9.2M	11.3M	12.6M	12M	3.1M
Accounts Payable	1.6M	2.8M	5.9M	3.2M	3M	3M	2.6M	3.1M	3.5M	4.2M	3.4M	4.7M	4M	3.7M	10.4M	9.2M	10M	9.2M	4.2M	2.5M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31K	0.0	0.0	0.0	0.0	0.0	1.3M	3.4M	7.8M	560K
Accrued Expenses	0.0	6.2M	4.7M	15.3M	12.6M	7.3M	5M	4.1M	4.8M	5.1M	3.8M	2.9M	3.6M	3.5M	7.4M	13.7M	16.9M	12.6M	10.7M	4.1M
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	1.2M	0.0	0.0	-425K	-425K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	2.9M	2.8M	3.8M	5.4M	4.1M	2.6M	1.2M	242K	0.0	425K	425K	0.0	0.0	0.0	0.0	0.0	5.4M	5.2M	4.5M	1.6M
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	7M	350K	10.1M	13.7M	2.6M	1.8M	57K	3.9M	12.3M	1.7M	6.1M	3.5M	2M	2.2M	3.8M	4.5M	15.4M	10.6M	5.5M	4.3M
Other Current Liabilities	13.8M	11.4M	11.2M	11.5M	11.1M	10.3M	5.4M	5.8M	4.4M	940K	1.1M	2.6M	1.6M	6.9M	6.8M	0.0	0.0	1.4M	1.5M	623K
Total Current Liabilities	25.3M	23.6M	35.8M	49.1M	33.4M	25M	15.4M	17.1M	25M	12.4M	14.8M	13.7M	11.2M	16.3M	28.3M	27.5M	49M	42.4M	34.2M	13.7M
NON-CURRENT LIABILITIES
Long Term Debt	40.1M	28.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-132.7M	0.0	0.0
Deferred Revenue (Non-Current)	360K	100K	640K	16.9M	3.7M	3M	2M	3.4M	1.5M	1.1M	3.1M	3.8M	1.1M	1.3M	1.5M	5.1M	9.3M	13.6M	18.9M	3.1M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-885K	-1.3M	0.0	0.0	0.0	0.0	0.0	0.0	132.7M	132.7M	77.5M
Other Non-Current Liabilities	1.3M	1.3M	1.2M	1.4M	1.3M	1.3M	1.2M	1.5M	2.3M	3.1M	3.8M	4.3M	5M	3.9M	3.5M	1.4M	1.3M	-130M	2.3M	2.6M
Total Non-Current Liabilities	72M	58.4M	14.1M	56.5M	48.6M	26.6M	28.2M	4.9M	4.1M	4.2M	6.9M	8.1M	6.2M	5.2M	4.9M	6.5M	13.2M	157.6M	166.8M	85.8M
Capital Lease Obligations	33.1M	31M	16M	43.6M	47.7M	25M	26.1M	61K	302K	425K	425K	0.0	0.0	0.0	0.0	0.0	7.9M	13.3M	17.4M	4.1M
Total Liabilities	97.3M	82.1M	49.9M	105.6M	82M	51.5M	43.6M	22M	29.1M	16.5M	21.8M	21.8M	17.4M	21.5M	33.2M	33.9M	62.2M	200M	201M	99.4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	141.3M	0.0	0.0	0.0	0.0
Common Stock	9K	8K	7K	6K	6K	6K	6K	5K	5K	4K	4K	4K	4K	4K	4K	4K	3K	0.0	0.0	0.0
Additional Paid-In Capital	657.3M	629.7M	584.1M	566.1M	552.1M	536.5M	447.9M	386.8M	340.1M	311.2M	306M	302.4M	298.4M	294.1M	287.8M	275.5M	15M	10.1M	6.2M	2.5M
Retained Earnings	-606.8M	-562.8M	-497.5M	-421.3M	-387.7M	-366.4M	-342.4M	-330.5M	-315.1M	-292.1M	-283.5M	-275.9M	-256.9M	-215.6M	-184.7M	-168.1M	-159.6M	-139.3M	-94.2M	-55.2M
Accumulated Other Comprehensive Income/Loss	8K	52K	0.0	0.0	0.0	0.0	0.0	0.0	-472K	0.0	405K	-142K	-32K	-136K	-407K	-34K	-252K	139K	537K	-52K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	249.7M	0.0	0.0	0.0
Total Stockholders' Equity	50.5M	66.9M	86.6M	144.8M	164.4M	170.1M	105.5M	56.3M	24.5M	19.1M	22.9M	26.3M	41.5M	78.4M	102.7M	107.4M	36.8M	-129.1M	-87.5M	-52.8M
Total Equity	50.5M	66.9M	86.6M	144.8M	164.4M	170.1M	105.5M	56.3M	24.5M	19.1M	22.9M	26.3M	41.5M	78.4M	102.7M	107.4M	36.8M	-129.1M	-87.5M	-52.8M
SUMMARY
Total Liabilities & Equity	147.8M	149M	136.6M	250.4M	246.4M	221.6M	149.1M	78.3M	53.6M	35.6M	44.6M	48.1M	58.8M	100M	135.9M	141.3M	99M	70.9M	113.5M	46.7M
Total Investments	29.9M	57M	9.7M	20.5M	14M	2.5M	1.1M	588K	671K	1.1M	1.5M	688K	3.8M	17.1M	38.1M	0.0	23.8M	15.2M	29M	0.0
Total Debt	73.2M	59.9M	16M	43.6M	47.7M	25M	26.1M	61K	302K	425K	425K	0.0	0.0	0.0	0.0	0.0	7.9M	13.3M	17.4M	4.1M
Net Debt	22.4M	40.6M	-49.1M	-70.3M	-69.1M	-124.2M	-64.4M	-53M	-30.9M	-18.8M	-22.8M	-26.5M	-22.1M	-32M	-25.8M	-72.4M	-23.8M	-8.6M	-37.7M	-28.2M
Shares Outstanding	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516	80,286,516

SEC Filings

CDXS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 14, 2026	April 08, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 11, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 11, 2026	March 11, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 05, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 13, 2025	August 13, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 13, 2025	June 30, 2025	2025	View Filing

Showing 1 to 10 of 283 filings

Related Guides

Blog Categories

Continue your CDXS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.